• Explore /
  • Poster
  • / Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.

Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.

Abstract Poster

Authors

null

Jeremy David Shapiro

Department of Medical Oncology, Cabrini Hospital, Melbourne, Australia

Jeremy David Shapiro , Subotheni Thavaneswaran , Craig Underhill , Kristy Pamela Robledo , Christos Stelios Karapetis , Fiona Lee Day , Louise M. Nott , Michael Jefford , Lorraine A. Chantrill , Nick Pavlakis , Niall C. Tebbutt , Timothy Jay Price , Mustafa Khasraw , Guy A. Van Hazel , Paul Michael Waring , Sabine Tejpar , John Simes , Val Gebski , Jayesh Desai , Eva Segelov

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

ACTRN12612000901808

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3572)

DOI

10.1200/JCO.2017.35.15_suppl.3572

Abstract #

3572

Poster Bd #

195

Abstract Disclosures

Similar Posters

First Author: Chiara Cremolini

First Author: B. Chibaudel

First Author: Samuel A. Jacobs

First Author: John H. Strickler